<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03004326</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5563</org_study_id>
    <secondary_id>U54AR057319</secondary_id>
    <nct_id>NCT03004326</nct_id>
  </id_info>
  <brief_title>Clinical Transcriptomics in Systemic Vasculitis (CUTIS)</brief_title>
  <acronym>CUTIS</acronym>
  <official_title>Clinical Transcriptomics in Systemic Vasculitis (CUTIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Merkel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Rare Diseases Research (ORDR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center observational study to evaluate the histopathology and transcriptome of
      cutaneous lesions in patients with several different types of vasculitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study employs a multi-center approach to evaluate cutaneous vasculitis across several
      forms of idiopathic vasculitis. Patients with cutaneous manifestations of vasculitis will be
      evaluated by teams of primary vasculitis care providers and Dermatologists in order to
      facilitate optimal selection of patients and sampling of lesions.

      A punch skin biopsy at a site of active vasculitis will be the source of material for
      histopathologic and transcriptomic evaluation. The histopathology of cutaneous vasculitis
      will be characterized using a standardized approach.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of clinical data and linked biopsy specimens</measure>
    <time_frame>1 year</time_frame>
    <description>Describe cutaneous vasculitis across several different forms of systemic vasculitis using histopathology.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cryoglobulinemic Vasculitis (CV)</condition>
  <condition>Drug-induced Vasculitis</condition>
  <condition>Eosinophilic Granulomatosis With Polyangiitis (EGPA)</condition>
  <condition>IgA Vasculitis</condition>
  <condition>Isolated Cutaneous Vasculitis</condition>
  <condition>Granulomatosis With Polyangiitis (GPA)</condition>
  <condition>Microscopic Polyangiitis (MPA)</condition>
  <condition>Polyarteritis Nodosa (PAN)</condition>
  <condition>Urticarial Vasculitis</condition>
  <condition>Vasculitis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be collected solely for research purposes. The reason we are performing
      these laboratory-based research studies is to help us better understand whether abnormalities
      detected in a subjects skin biopsy can also be detected in their blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        About 56 people with vasculitis will take part in this study at approximately 20 medical
        centers across North America. Patients with CV, DiV, EGPA, IgA vasculitis, GPA, MPA, PAN,
        isolated cutaneous vasculitis and urticarial vasculitis will potentially be enrolled into
        this study.

        The protocol will be conducted at the major vasculitis centers in the United States and
        Canada participating in selected VCRC studies. Skin biopsy specimens collected as standard
        of care for these diseases will be retrieved and used in research.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a cutaneous lesion (purpuric macules, palpable purpura, retiform purpura,
             nodules, ulcers, or urticarial) believed to be related to active vasculitis

          -  Have a suspected or confirmed diagnosis of:

               -  Cryoglobulinemic vasculitis (CV)

               -  Drug-induced vasculitis

               -  Eosinophilic granulomatosis with polyangiitis (EGPA)

               -  IgA vasculitis

               -  Isolated cutaneous vasculitis

               -  Granulomatosis with polyangiitis (GPA)

               -  Microscopic polyangiitis (MPA)

               -  Polyarteritis nodosa (PAN)

               -  Urticarial vasculitis

          -  Be willing and able to provide written informed consent (or assent for those under

        Exclusion Criteria:

          -  You are less than five years old

          -  Considered not to be a candidate for a biopsy or have a higher risk of developing an
             infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for
             you participating in this study do not outweigh the potential benefit of learning
             information from your biopsy

          -  You have a neutrophil count (type of white blood cell) less than 1500/mm3, platelet
             count less than 50,000/mm3, or a hemoglobin less than 7 g/dL

          -  You have an uncontrolled disease that could prevent you from completing the study
             procedures

          -  You have an active infection at or near the potential biopsy site, have poor
             circulation, or have bony prominence or other structure that would increase your risk
             of complications if you participated in this study

          -  You are pregnant or nursing

          -  You are not able to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Micheletti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Grayson, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The National Institute of Arthritis and Musculoskeletal and Skin Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol McAlear, MA</last_name>
    <email>cmcalear@upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tandy Ramirez</last_name>
      <email>ItandewyRamirez@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Zammitti</last_name>
      <email>zammitti@bu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Pierce</last_name>
      <email>pierce.katrina@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Ward</last_name>
      <email>waran@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hampton</last_name>
      <email>michelle.hampton@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Webber</last_name>
      <email>lisa.webber@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Toronto Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Vendramini</last_name>
      <email>judy.vendramini@sinaihealthsystem.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rarediseasesnetwork.org/vcrc</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Merkel</investigator_full_name>
    <investigator_title>Chief, Division of Rheumatology Professor of Medicine and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>DIV</keyword>
  <keyword>CSS</keyword>
  <keyword>EGPA</keyword>
  <keyword>HSP</keyword>
  <keyword>GPA</keyword>
  <keyword>MPA</keyword>
  <keyword>PAN</keyword>
  <keyword>Wegeners</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Polyarteritis Nodosa</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
    <mesh_term>Cryoglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

